

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

SYH2059 TABLETS OBTAINS CLINICAL TRIAL APPROVAL

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that SYH2059 Tablets (the “**Product**”) developed by the Group has obtained approval granted by the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China.

The Product developed by the Group’s innovative small molecule drug design platform is a novel, highly active and highly selective cyclic nucleotide phosphodiesterase 4B (PDE4B) inhibitor with complete independent intellectual property rights. PDE4B inhibitor exerts anti-inflammatory and anti-fibrotic effects by regulating the release of inflammatory cytokines and inhibiting fibroblast proliferation and differentiation. The indication for this clinical trial approval is interstitial lung disease (including but not limited to idiopathic pulmonary fibrosis and progressive pulmonary fibrosis). Preclinical studies demonstrated that the selectivity and activity of the Product for the PDE4B target were significantly better than other drugs with the same target, and its efficacy in animal models of human disease was also distinctly better than the existing drugs, with good pharmacokinetic characteristics and safety profile.

Currently, there are few drugs on the market available for the treatment of interstitial lung disease, and patients have limited benefit from these treatments. The Product has the potential to become an effective drug for the treatment for this disease, providing a promising clinical development value.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 7 January 2025

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin and Mr. CHEN Weiping as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.